Institutional members access full text with Ovid®

Share this article on:

Systemic Chemotherapy in Patients With Renal Failure

Bekele, Lishan B.A.; Vazquez, Marieberta Vidal B.S.; Adjei, Alex A. M.D., Ph.D.

American Journal of Clinical Oncology: August 2001 - Volume 24 - Issue 4 - p 382–384

The administration of systemic chemotherapy to patients with moderate‐to‐severe organ impairment remains a challenge. In renal failure, guidelines for dose adjustments exist for very few chemotherapy agents. Subsequently, oncologists typically withhold treatment with systemic chemotherapy for patients with severe renal dysfunction. We present the case of a patient with metastatic transitional cell carcinoma of the bladder and renal failure who underwent successful systemic chemotherapy with paclitaxel and carboplatin. The data on systemic chemotherapy in patients with severe renal dysfunction are reviewed.

From the Mayo Medical School (L.B., A.A.A.) and Mayo Clinic (A.A.A.), Rochester, Minnesota; and UPR School of Medicine (M.V.V.), San Juan, Puerto Rico.

Supported in part by grant CA77112 from the National Cancer Institute. M.V.V. was a Minority Mayo Scholar Summer Student.

Address correspondence and reprint requests to Dr. Alex A. Adjei, Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, U.S.A.

© 2001 Lippincott Williams & Wilkins, Inc.